PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
10.71%
Some net income increase while AVXL is negative at -861.17%. John Neff would see a short-term edge over the struggling competitor.
-1.40%
Negative yoy D&A while AVXL is 0.00%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
No Data
No Data available this quarter, please select a different quarter.
-49.10%
Negative yoy SBC while AVXL is 6452.67%. Joel Greenblatt would see less immediate dilution advantage if talent levels remain strong.
5.95%
Slight usage while AVXL is negative at -1248.31%. John Neff would note competitor possibly capturing more free cash unless expansions are needed here.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-23.80%
Negative yoy AP while AVXL is 0.00%. Joel Greenblatt would see quicker payments or less reliance on trade credit than competitor, unless expansions are hindered.
823.30%
Some yoy usage while AVXL is negative at -1248.31%. John Neff would see competitor possibly generating more free cash from minor accounts than we do.
59.87%
Lower 'other non-cash' growth vs. AVXL's 64833.90%, indicating steadier reported figures. David Dodd would confirm no missed necessary write-downs or gains.
-19.06%
Negative yoy CFO while AVXL is 4.49%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
96.37%
CapEx growth of 96.37% while AVXL is zero at 0.00%. Bruce Berkowitz would see a mild cost burden that must yield returns in future revenue or margins.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-58.44%
We reduce yoy invests while AVXL stands at 0.00%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
92.69%
Debt repayment growth of 92.69% while AVXL is zero at 0.00%. Bruce Berkowitz sees a mild advantage that can reduce interest costs unless expansions demand capital here.
-1494.87%
Negative yoy issuance while AVXL is 0.00%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.